MedTrace Logo

IC14 in Adult Patients With Dengue Fever

NCT03875560 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2026-05-05

No results posted yet for this study

Summary

Randomized, double-blind, placebo-controlled, safety, PK/PD and preliminary efficacy study of intravenous IC14 in adult patients in a dengue-endemic region presenting with fever \> 38°C for \< 48 hours with a positive NS1 strip assay or reverse-transcriptase polymerase chain reaction assay for dengue virus.

Conditions

  • Dengue Fever

Interventions

BIOLOGICAL

IC14

recombinant chimeric anti-human CD14 monoclonal antibody

DRUG

Placebo

Inactive

Sponsors & Collaborators

  • Implicit Bioscience

    lead INDUSTRY

Principal Investigators

  • Jan Agosti, MD · Implicit Bioscience

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-31
Primary Completion
2020-01-31
Completion
2020-06-30
FDA Drug
Yes

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03875560 on ClinicalTrials.gov